Kansas City, Missouri 2021-10-14 10:13:59 –
In the next two days, a panel of major independent Food and Drug Administrations will be able to take steps to approve booster shots of both Moderna and Johnson & Johnson COVID-19 vaccines.
The FDA’s Vaccine and Related Biopharmaceutical Advisory Board (VRBPAC) will meet Thursday to discuss the benefits and risks of recommending a booster dose of Moderna’s COVID-19 vaccine. The meeting is expected to end with the first non-binding vote on issuing formal recommendations for shots.
On Friday, the Commission will meet again for a similar discussion on Johnson & Johnson’s booster shots.
according to ABC newsIf the panel voted to recommend either vaccine type booster shot, the issue goes to the FDA as a whole.
The FDA then issues a formal recommendation that raises questions to the Centers for Disease Control and Prevention’s Immunization Implementation Advisory Board. The committee will discuss the Moderna booster on October 20th and the Johnson & Johnson booster on October 21st. .. Finally, CDC Director Dr. Rochelle Walensky needs to make a final recommendation for full approval.
ABC News estimates that the earliest booster shots may be approved for emergency use is October 22nd.
New York Times VRBPAC reports that it is likely to recommend Johnson & Johnson Vaccine Booster due to its slightly lower efficacy rate. The data also show that people who receive the Moderna vaccine are less susceptible to severe cases of COVID-19 months after the last dose than other vaccines.
Friday’s VR BPAC also weighs a new report from the National Institutes of Health. Mixing and matching of different types of vaccines and booster immune doses Still, it showed a strong antibody reaction.
“These data suggest that if the vaccine is approved or approved for booster immunization, an immune response will be generated regardless of the major COVID-19 vaccination regimen,” the researchers write. ..
The study has not yet been peer-reviewed.
FDA and CDC Already approved booster shots For the Pfizer COVID-19 vaccine for people over the age of 65, people with underlying illness, and people doing important work. The FDA states that these Americans should look for Pfizer boosters six months after the second dose.
Key FDA panel meeting to discuss Moderna, J&J boosters Source link Key FDA panel meeting to discuss Moderna, J&J boosters